StreetAlpha.app
Home › Stocks › OMER

Omeros Corp (OMER)

Healthcare
$13.21
▼ −5.71%
LAST CLOSE · NOV 20

Omeros is a Seattle biotechnology company that develops drugs targeting the complement system, including its approved treatment YARTEMLEA. It last closed at $13.21 on Nov 20, down 5.71% on the day. The next earnings report for OMER is expected around Tue, Mar 30, 2027, after the close. For the quarter ended Sep 2026, OMER reported EPS of -$0.79 on revenue of $35.9M. Over its last 8 reports the stock moved an average of 15.1% the session after earnings. Over the last 12 months OMER insiders bought $0 of stock on the open market and sold $3.0M, according to SEC Form 4 filings.

AI Auto Pilots
Is OMER in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold OMER.

Key Stats

Last 12 months
Results
Net income
$98.4M
EPS (diluted)
$1.55
Free cash flow
−$37.0M
Valuation
Market cap
$983.7M
74.5M shares
P/E
8.5
Price over 12 month EPS
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$5.1M
At Sep 30
Shareholder equity
−$90.0M
Buybacks
$9.9M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $194.2M$194.2MFY2021FY2022: $47.4M$47.4MFY2022FY2023: −$117.8M−$117.8MFY2023FY2024: −$156.8M−$156.8MFY2024FY2025: −$3.4M−$3.4MFY2025

From OMER's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Mar 30
Estimated date · After the close
Reported EPS
-$0.79
Quarter ended Sep 2026
Year ago EPS
-$0.47
Same quarter last year
Revenue
$35.9M
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.55Dec '24Mar 2025: -$0.58Mar '25Jun 2025: -$0.43Jun '25Sep 2025: -$0.47Sep '25Dec 2025: $1.42Dec '25Mar 2026: $0.62Mar '26Jun 2026: $0.15Jun '26Sep 2026: -$0.79Sep '26Latest -$0.79
Revenue by quarter
Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Mar 2026: $9.9MMar '26Jun 2026: $28.5MJun '26Sep 2026: $35.9MSep '26Latest $35.9M
How OMER moved after its last 8 reports
Average move the session after a report ±15.1%
Nov 16, 2026After the close−16.6%
Aug 12, 2026After the close+26.6%
May 13, 2026After the close−7.7%
Mar 31, 2026After the close+14.4%
Jan 7, 2026After the close−4.5%
Nov 13, 2025After the close+25.3%
Aug 14, 2025After the close+7.0%
May 15, 2025After the close−18.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on OMERStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on OMER: 0 upgrades, 0 downgrades, 0 initiations
HC WainwrightReiterated
Nov 20Buy 

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on OMER
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on OMER

Technical Analysis

OMER · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, oversold

The stock is 28% below its 20 day and 35% below its 50 day average. It is 5% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), oversold. The nearest support is the Pivot S1 at $12.89, and the nearest resistance the Pivot at $13.39.

Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityHigh, 8.1%/day
Key levels
$21.2452 week high+60.8%
$18.14Swing high (Aug 13)+37.3%
$17.8350 day average+35.0%
$16.9120 day average+28.0%
$16.04100 day average+21.4%
$13.84200 day average+4.8%
$13.70Pivot R1+3.7%
$13.39Pivot+1.4%
$13.21Last close
$12.89Pivot S1−2.4%
$12.70Swing low (Nov 17)−3.9%
$6.7052 week low−49.3%
Indicators
RSI (14)30.51Weak, oversold below 30Neutral
MACD-0.95Below its signal lineBearish
Stochastic19.8Near the bottom of its rangeOversold
ADX (14)21.5Weak trend
Williams %R-91.6Oversold below −80, overbought above −20Oversold
CCI (20)-190.3Oversold below −100, overbought above 100Oversold
Rate of change−21.9%Change over 10 sessionsBearish
ATR (14)$1.07Typical daily range, 8.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for OMER

What happened before

See how OMER did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow OMER usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How OMER has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2009.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for OMERHow many large options trades hit OMER, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

OMER Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲104 buying vs 74 selling
  • ▲Held by funds +1.4 pts
  • ▲Funds holding +18
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding192174+10.3%
In funds' top 1032+50.0%
Held by funds55.8%54.3%+1.4 pts
New / increased41 / 6334 / 68+2.0%
Reduced / sold out49 / 2539 / 25+15.6%
Put/call ratio4.4412.31−63.9%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OMER institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

OMER Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$3.0M8 sales · 4 insiders
26% of the selling was under pre-arranged trading plans.
2026-01 sold $751K2026-05 sold $87K2026-08 sold $1.8M2026-09 sold $419KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 23David J. BorgesVP, Finance & CAOSale plan20,000$20.95$419K
Aug 31Peter B CancelmoVP, General CounselSale50,000$18.59$930K
Aug 27Arnold C HanishDirectorSale15,000$18.81$282K
Aug 24David J. BorgesVP, Finance & CAOSale plan10,906$18.96$207K
Aug 20Thomas J. CableDirectorSale15,000$18.45$277K
Aug 13David J. BorgesVP, Finance & CAOSale plan5,000$16.95$85K
Every insider buy and sale for OMER over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See OMER insider trades →

From SEC Form 4 filings by OMER's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OMER is in one of them and how their past OMER trades turned out.

OMER in the AI portfolios
Loading…

OMER News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OMER in an article yet. Here's the latest on the wider market.

OMER in the news

About Omeros

Omeros is a biotechnology company based in Seattle, Washington, that develops drugs aimed at the complement system, a part of the body's immune system. Its approved product, YARTEMLEA, treats thrombotic microangiopathy, a serious complication that can follow stem cell transplants, and it is sold for use in the United States. The company is also developing treatments for other immune conditions and for addiction. Its customers are patients and the hospitals and doctors who treat them.

Headquarters
Seattle, WA